Výsledky vyhledávání - "Mark P. Chao"

Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia

Autor: Andriana G. Kotini, Saul Carcamo, Nataly Cruz-Rodriguez, Malgorzata Olszewska, Tiansu Wang, Deniz Demircioglu, Chan-Jung Chang, Elsa Bernard, Mark P. Chao, Ravindra Majeti, Hanzhi Luo, Michael G. Kharas, Dan Hasson, Eirini P. Papapetrou

Publikováno v: Blood Cancer Discovery. :OF1-OF18

The reprogramming of human acute myeloid leukemia (AML) cells into induced pluripotent stem cell (iPSC) lines could provide new faithful genetic models of AML, but is currently hindered by low success rates and uncertainty about whether iPSC-derived

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e509ad52fba71aa507e7a6b94bb331a
https://doi.org/10.1158/2643-3230.bcd-22-0167

Zobrazit plný text záznamu

Akademický článek

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Autor: Mark P. Chao, Chris H. Takimoto, Dong Dong Feng, Kelly McKenna, Phung Gip, Jie Liu, Jens-Peter Volkmer, Irving L. Weissman, Ravindra Majeti

Publikováno v: Frontiers in Oncology, Vol 9 (2020)

In recent years, immunotherapies have been clinically investigated in AML and other myeloid malignancies. While most of these are focused on stimulating the adaptive immune system (including T cell checkpoint inhibitors), several key approaches targe

Externí odkaz: https://doaj.org/article/8638e8ad243d4633b048ad522ad22867

Zobrazit plný text záznamu

Data from Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

Autor: Ravindra Majeti, Irving L. Weissman, Christopher Y. Park, Feifei Zhao, Rachel Weissman-Tsukamoto, Max Jan, Chad Tang, Ash A. Alizadeh, Mark P. Chao

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and constitutes 15% of adult leukemias. Although overall prognosis for pediatric ALL is favorable, high-risk pediatric patients and most adult patients have significantly wors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5572acf0c696d1ec46c355e1d1382f07
https://doi.org/10.1158/0008-5472.c.6503187.v1

Zobrazit plný text záznamu

A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia

Autor: Andrew H. Wei, Guan Xing, Camille Renard, Mark P. Chao, Naval Daver, David A. Sallman, Paresh Vyas, Giridharan Ramsingh

Background: Magrolimab (Hu5F9-G4) is an antibody blocking CD47, a macrophage immune checkpoint and "don't eat me" signal on cancer cells, that eliminates leukemia stem cells by inducing tumor phagocytosis. Hypomethylating agents synergize with magrol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f4b1b1692d16995bf2cad8065fbae46
https://doi.org/10.1182/blood-2021-145208

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání